Shares of Oncolytics Biotech Inc. (TSE:ONC – Get Free Report) reached a new 52-week low on Tuesday . The stock traded as low as C$0.86 and last traded at C$0.86, with a volume of 47955 shares trading hands. The stock had previously closed at C$0.89.
Oncolytics Biotech Stock Up 1.1 %
The stock’s fifty day simple moving average is C$1.06 and its two-hundred day simple moving average is C$1.29. The company has a debt-to-equity ratio of 11.75, a current ratio of 2.99 and a quick ratio of 8.86. The company has a market capitalization of C$69.37 million, a price-to-earnings ratio of -2.51 and a beta of 1.35.
Oncolytics Biotech Company Profile
Oncolytics Biotech Inc, a clinical-stage biopharmaceutical company, focuses on the discovery and development of pharmaceutical products for the treatment of cancer. The company is developing pelareorep, an intravenously delivered immunotherapeutic agent, which is in phase 3 clinical trial for the treatment of hormone receptor-positive / human epidermal growth factor 2-negative metastatic breast cancer and advanced/metastatic pancreatic ductal adenocarcinoma.
Featured Articles
- Five stocks we like better than Oncolytics Biotech
- Stock Ratings and Recommendations: Understanding Analyst Ratings
- Everything About Amazon Stock Signals a Buy—Time to Load Up?
- 3 Healthcare Dividend Stocks to Buy
- 5 Reasons Five Below’s Stock Price Is Heading Higher This Year
- Expert Stock Trading Psychology Tips
- Broadcom: Why the Chip Stock Remains a Top Long-Term AI Play
Receive News & Ratings for Oncolytics Biotech Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Oncolytics Biotech and related companies with MarketBeat.com's FREE daily email newsletter.
